{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:05:26Z","timestamp":1756634726812,"version":"3.43.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06385-z","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T03:14:56Z","timestamp":1747365296000},"page":"3893-3898","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inotuzumab therapy resulted in molecular remission of relapsed\/resistant B-cell acute lymphoblastic leukemia with BCR::ABL1 Lys404Glu mutation"],"prefix":"10.1007","volume":"104","author":[{"given":"Krzysztof","family":"Lewandowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Janicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Bara\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"Kandu\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Godziewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Kiernicka-Parulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Ludwik\u00f3w","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna I.","family":"Loch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"6385_CR1","doi-asserted-by":"crossref","unstructured":"Baer C, Meggendorfer M, Haferlach C, Kern W, Haferlach T (2022) Detection of ABL1 kinase domain mutations in therapy-na\u00efve BCR-ABL1-positive acute lymphoblastic leukemia. Haematologica 107(2):562. Available from: \/pmc\/articles\/PMC8804577\/. cited 2024 Oct 3","DOI":"10.3324\/haematol.2021.279807"},{"key":"6385_CR2","doi-asserted-by":"crossref","unstructured":"Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A et al (2007) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 110(2):727\u201334. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17405907\/. cited 2024 Oct 3","DOI":"10.1182\/blood-2006-11-052373"},{"key":"6385_CR3","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Ros\u00e9e P, M\u00fcller MC, Lahaye T et al (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16(11):2190\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12399961\/. cited 2024 Oct 3","DOI":"10.1038\/sj.leu.2402741"},{"key":"6385_CR4","doi-asserted-by":"crossref","unstructured":"Roskoski R (2016) Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res 103:26\u201348. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26529477\/. cited 2024 Oct 3","DOI":"10.1016\/j.phrs.2015.10.021"},{"key":"6385_CR5","doi-asserted-by":"crossref","unstructured":"Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J et al (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77(1):1\u201311. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21118377\/. cited 2024 Oct 3","DOI":"10.1111\/j.1747-0285.2010.01054.x"},{"key":"6385_CR6","doi-asserted-by":"crossref","unstructured":"Rossari F, Minutolo F, Orciuolo E (2018) Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol 11(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29925402\/. cited 2024 Oct 3","DOI":"10.1186\/s13045-018-0624-2"},{"key":"6385_CR7","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401\u201312. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19878872\/. cited 2022 Feb 1"},{"key":"6385_CR8","doi-asserted-by":"crossref","unstructured":"Lewandowski K (2024) Asciminib a new player in treatment of TKI-resistant\/intolerant chronic phase chronic myelogenous leukemia. Acta Haematol Pol 55(2):62\u201372. Available from: https:\/\/journals.viamedica.pl\/acta_haematologica_polonica\/article\/view\/98474. cited 2024 Dec 30","DOI":"10.5603\/ahp.98474"},{"key":"6385_CR9","doi-asserted-by":"crossref","unstructured":"Leyte-Vidal A, Garrido Ruiz D, DeFilippis RA, Leske IB, Rea D, Phan S et al (2024) BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood 144(6):639\u201345. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38643492\/. cited 2024 Nov 26","DOI":"10.1182\/blood.2023022538"},{"key":"6385_CR10","doi-asserted-by":"crossref","unstructured":"Stock W, Martinelli G, Stelljes M, DeAngelo DJ, G\u00f6kbuget N, Advani AS et al (2021) Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome\u2013positive relapsed\/refractory acute lymphoblastic leukemia. Cancer 127(6):905. Available from: \/pmc\/articles\/PMC7983935\/. cited 2024 Oct 4","DOI":"10.1002\/cncr.33321"},{"key":"6385_CR11","unstructured":"Jain N, Cortes JE, Ravandi F, Konopleva M, Alvarado Y, Kadia T et al (2017) Inotuzumab ozogamicin in combination with bosutinib for patients with relapsed or refractory Ph+ aLL or CML in lymphoid blast phase. Blood 130"},{"key":"6385_CR12","doi-asserted-by":"crossref","unstructured":"Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G et al (2017) Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk 17(12):897\u2013901. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28927784\/. cited 2024 Oct 4","DOI":"10.1016\/j.clml.2017.08.101"},{"key":"6385_CR13","doi-asserted-by":"crossref","unstructured":"Liu W, Wang C, Ouyang W, Hao J, Ren J, Peng L et al (2024) Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed\/refractory disease. Br J Haematol 205(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39363594\/. cited 2025 Apr 11","DOI":"10.1111\/bjh.19804"},{"key":"6385_CR14","doi-asserted-by":"publisher","unstructured":"Patel AA, Duvall AS, Saygin C, Weiner H, Dworkin E, Noorani A et al (2024) Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood 144(Supplement 1):1432\u20131432. Available from: https:\/\/doi.org\/10.1182\/blood-2024-193442. cited 2025 Apr 11","DOI":"10.1182\/blood-2024-193442"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06385-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T04:08:13Z","timestamp":1754626093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06385-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6385"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06385-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from patient included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}